Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,687,140
  • Shares Outstanding, K 106,392
  • Annual Sales, $ 7,863 M
  • Annual Income, $ 2,116 M
  • 60-Month Beta 0.51
  • Price/Sales 7.79
  • Price/Cash Flow 23.77
  • Price/Book 6.76
Trade REGN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 9.52
  • Number of Estimates 1
  • High Estimate 9.52
  • Low Estimate 9.52
  • Prior Year 5.84
  • Growth Rate Est. (year over year) +63.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
551.00 +5.23%
on 09/25/20
619.97 -6.48%
on 10/05/20
+14.62 (+2.59%)
since 09/23/20
3-Month
540.00 +7.37%
on 09/11/20
660.00 -12.15%
on 08/05/20
-50.50 (-8.01%)
since 07/23/20
52-Week
299.22 +93.77%
on 10/24/19
664.64 -12.76%
on 07/20/20
+274.79 (+90.09%)
since 10/23/19

Most Recent Stories

More News
SmarTrend Watching for Potential Rebound in Shares of Regeneron Pharm After 2.42% Loss

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $567.00 to a high of $577.00. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of...

REGN : 579.81 (+0.71%)
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.

BIIB : 265.00 (-0.67%)
REGN : 579.81 (+0.71%)
GILD : 60.79 (+0.20%)
VRTX : 211.58 (+0.71%)
BSTC : 88.16 (+0.05%)
CRSP : 92.65 (+2.76%)
Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty (REGN)

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, continues to investigate whether certain directors and officers of Regeneron Pharmaceuticals,...

REGN : 579.81 (+0.71%)
3 Top Genomics Stocks to Buy for 2021 and Beyond

Genomics is a medical industry predicted to significantly grow over the next 7 years. To get involved, consider adding Regeneron Pharmaceuticals (REGN), CRISPR Therapeutics (CRSP) and Invitae Corporation...

REGN : 579.81 (+0.71%)
CRSP : 92.65 (+2.76%)
NVTA : 45.26 (-1.63%)
Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion

Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.

REGN : 579.81 (+0.71%)
GILD : 60.79 (+0.20%)
NVS : 84.43 (+0.02%)
VRTX : 211.58 (+0.71%)
Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis

Regeneron (REGN) gets positive CHMP opinion for Dupixent, recommending extending the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis.

REGN : 579.81 (+0.71%)
SNY : 49.33 (+0.82%)
EBS : 96.11 (-1.58%)
CSTL : 51.84 (+0.97%)
2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium (Virtual)

Join us as we discuss today's pressing healthcare issues.

CVS : 60.25 (+1.29%)
MRNA : 70.53 (-0.44%)
PFE : 38.18 (+2.00%)
REGN : 579.81 (+0.71%)
TDOC : 216.32 (+0.71%)
GBL : 12.63 (-1.25%)
Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran

Alnylam (ALNY) gets positive opinion from the CHMP for lumasiran for the treatment of primary hyperoxaluria type 1.

REGN : 579.81 (+0.71%)
ALNY : 131.84 (-1.83%)
NVS : 84.43 (+0.02%)
EBS : 96.11 (-1.58%)
Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod

Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).

REGN : 579.81 (+0.71%)
SNY : 49.33 (+0.82%)
RHHBY : 41.0300 (+0.20%)
ABBV : 84.34 (+0.04%)
Eiger (EIGR) Up on Positive Results From Coronavirus Study

Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.

REGN : 579.81 (+0.71%)
MRK : 79.83 (+0.78%)
BMY : 60.13 (-1.04%)
EIGR : 10.09 (+1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 586.82
1st Resistance Point 583.31
Last Price 579.81
1st Support Level 575.71
2nd Support Level 571.62

See More

52-Week High 664.64
Last Price 579.81
Fibonacci 61.8% 525.05
Fibonacci 50% 481.93
Fibonacci 38.2% 438.81
52-Week Low 299.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar